Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18660885 | BLETILLA STRIATA POLYSACCHARIDE IRON COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF | May 2024 | March 2025 | Abandon | 10 | 1 | 1 | No | No |
| 18417945 | NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONS | January 2024 | December 2024 | Allow | 10 | 2 | 1 | Yes | No |
| 18417989 | NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONS | January 2024 | May 2025 | Abandon | 16 | 2 | 1 | No | No |
| 18523274 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | November 2023 | April 2025 | Abandon | 16 | 1 | 1 | No | No |
| 18387552 | PYRIDINO-2,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 0 | 1 | No | No |
| 18373774 | COMBINATION THERAPY | September 2023 | June 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18458973 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | August 2023 | March 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18457738 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | August 2023 | June 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18233210 | NOVEL FEAZD, NIAZD, AND CUAZD COMPLEXES INCORPORATING 1-(2-HYDROXYPHENYLAZO)-2-NAPHTHOL (H2AZD) FOR BIOLOGICAL APPLICATIONS | August 2023 | May 2025 | Abandon | 21 | 4 | 1 | No | No |
| 18355684 | AMORPHOUS SOLID DISPERSION GANAXOLONE FORMULATION | July 2023 | December 2024 | Abandon | 17 | 2 | 1 | No | No |
| 18330402 | Ciliated protozoan with the effect of promoting plant seed germination and seedling growth | June 2023 | March 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18206290 | METHODS OF TREATING B-CELL PROLIFERATIVE DISORDER | June 2023 | September 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18203759 | METHODS OF TREATING B-CELL PROLIFERATIVE DISORDER | May 2023 | November 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18184228 | CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | March 2023 | December 2024 | Allow | 22 | 1 | 1 | No | No |
| 18121826 | METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY | March 2023 | April 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18173230 | THEAFLAVIN COMPOSITION CAPABLE OF PROMOTING WOUND HEALING AS WELL AS PREPARATION METHOD AND USE THEREOF | February 2023 | July 2024 | Abandon | 17 | 2 | 1 | No | No |
| 18105285 | Methods of Administering Belumosudil for Treatment of Chronic Graft Versus Host Disease | February 2023 | May 2024 | Allow | 15 | 2 | 1 | No | No |
| 18163041 | NANO-EMULSION OF CBF�-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER | February 2023 | June 2025 | Allow | 28 | 2 | 1 | No | No |
| 18098938 | METHODS OF TREATING B-CELL PROLIFERATIVE DISORDER | January 2023 | April 2023 | Allow | 3 | 0 | 1 | No | No |
| 18064767 | SUBLINGUAL FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID WITH CITRIC ACID, SODIUM BICARBONATE ,AND L-THEANINE FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION | December 2022 | June 2025 | Abandon | 30 | 1 | 1 | No | No |
| 18072747 | NOVEL KETOGENIC COMPOUNDS, COMPOSITIONS, METHODS AND USE THEREOF | December 2022 | February 2025 | Allow | 26 | 2 | 1 | No | No |
| 17977917 | SELF-PRESERVING TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING DIETHYLENE GLYCOL MONOETHYL ETHER | October 2022 | January 2024 | Abandon | 14 | 2 | 0 | Yes | No |
| 17973749 | PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY | October 2022 | November 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17893664 | COMPOSITION FOR CROP CARE AND PROTECTION | August 2022 | November 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17885105 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | August 2022 | December 2023 | Abandon | 17 | 2 | 1 | No | No |
| 17882014 | DRUG PRODUCTS FOR INTRANASAL ADMINISTRATION AND USES THEREOF | August 2022 | March 2024 | Abandon | 20 | 3 | 0 | Yes | No |
| 17866877 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | July 2022 | May 2024 | Abandon | 22 | 2 | 1 | Yes | Yes |
| 17758163 | FLOATING DRUG DELIVERY SYSTEMS COMPRISING CANNABINOIDS | June 2022 | June 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17850088 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONS | June 2022 | August 2023 | Abandon | 14 | 1 | 2 | No | No |
| 17824518 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB | May 2022 | December 2023 | Abandon | 19 | 3 | 1 | No | No |
| 17737929 | COMPOSITIONS AND METHODS FOR KELOIDLESS HEALING | May 2022 | October 2024 | Abandon | 29 | 0 | 1 | No | No |
| 17736386 | CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | May 2022 | December 2022 | Allow | 8 | 1 | 1 | No | No |
| 17732080 | OIL-IN-WATER EMULSION OF MOMETASONE | April 2022 | January 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17731920 | DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR | April 2022 | May 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17721909 | SURFACE-TREATING WOOD TO PREVENT DISCOLORATION | April 2022 | June 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17713596 | THERAPEUTIC HYDROGELS | April 2022 | March 2025 | Allow | 35 | 2 | 1 | No | No |
| 17703427 | GEL BASE COMPOSITION FOR COMPOUNDING INTO A MUCOADHESIVE DELIVERY SYSTEM | March 2022 | December 2023 | Abandon | 20 | 2 | 2 | Yes | No |
| 17578844 | METHODS AND COMPOSITIONS FOR USING CINNAMALDEHYDE AND ZINC FOR WEIGHT MANAGEMENT | January 2022 | December 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17645244 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | December 2021 | October 2022 | Abandon | 10 | 0 | 1 | No | No |
| 17540965 | Inorganic Nitrite to Improve Cardiopulmonary Hemodynamics | December 2021 | March 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17521928 | COMPOSITION FOR IMPROVING SKIN CONDITIONS | November 2021 | January 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17505902 | ANTIFUNGAL COMPOSITION HAVING EXCELLENT ANTIFUNGAL ACTIVITY EVEN AT LOW TEMPERATURE | October 2021 | December 2024 | Allow | 38 | 4 | 0 | No | No |
| 17604282 | ORAL DELIVERY SYSTEMS BASED ON IN SITU FORMING PROTEIN/POLYSACCHARIDE COACERVATES | October 2021 | April 2023 | Allow | 18 | 3 | 1 | Yes | No |
| 17501519 | TABLETS FOR ORAL SUSPENSION CONTAINING RIVAROXABAN | October 2021 | April 2025 | Abandon | 42 | 3 | 1 | Yes | Yes |
| 17448450 | METHODS FOR TREATMENT OF POST-SURGERY LAXITY OF TENDONS AND TENDON REPAIR | September 2021 | June 2023 | Abandon | 21 | 2 | 1 | Yes | No |
| 17480481 | METHODS AND APPARATUS FOR TREATING A WOUND | September 2021 | January 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17475489 | SUSTAINED RELEASE BUPRENORPHINE MICROSPHERES (SRBM) AND METHODS OF USE THEREOF | September 2021 | November 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17471524 | NEW ALKYNYL-SUBSTITUTED 3-PHENYLPYRROLIDINE-2,4-DIONES AND USE THEREOF AS HERBICIDES | September 2021 | October 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17463369 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | August 2021 | February 2024 | Abandon | 29 | 3 | 1 | No | Yes |
| 17398960 | Cosmetic Skin Cream and Medicine | August 2021 | June 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17388453 | CONTAINERIZED LIQUID FORMULATIONS | July 2021 | July 2025 | Allow | 47 | 3 | 1 | No | No |
| 17378041 | SOLID DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) COMPOSITIONS | July 2021 | February 2023 | Abandon | 19 | 3 | 1 | Yes | No |
| 17422448 | A METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION COMPRISING NEFOPAM AND ACETAMINOPHEN, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREBY | July 2021 | March 2025 | Abandon | 44 | 5 | 1 | Yes | No |
| 17373711 | RADIATION SENSITIZER OR ANTI-CANCER CHEMOTHERAPY SENSITIZER | July 2021 | February 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17372403 | INTRANASAL NANO INDUCER FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES AND METHOD THEREOF | July 2021 | October 2024 | Abandon | 40 | 2 | 1 | Yes | No |
| 16973000 | CHITOSAN GELS (A) CONTAINING METAL NANOPARTICLES OF COPPER, SILVER AND ANTIBIOTICS (CIPROFLOXACIN, CEFOTAXIME, GENTAMICIN AND CLOXACILLIN) | July 2021 | August 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17357058 | Fulvic Acid Sterilization Deodorant As Well As Preparation Method and Application Thereof | June 2021 | December 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17342645 | SUSTAINED RELEASE COMPOSITIONS COMPRISING LIOTHYRONINE | June 2021 | December 2023 | Allow | 30 | 6 | 1 | Yes | No |
| 17303736 | COMPOSITION AND METHOD TO PREVENT PATHOGEN TRANSMISSION THROUGH ALTERING SALIVA | June 2021 | May 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17331505 | METHODS OF ADMINISTERING ELAGOLIX IN ASSOCIATION WITH ARTIFICIAL REPRODUCTIVE TECHNOLOGIES | May 2021 | December 2022 | Abandon | 19 | 2 | 1 | Yes | No |
| 17327702 | METHODS OF TREATING EYE DISEASE WITH TOBRAMYCIN-RELATED COMPOSITIONS | May 2021 | November 2022 | Allow | 18 | 3 | 1 | Yes | No |
| 17302509 | Personal Care Composition with Zinc Phosphate Active | May 2021 | October 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17306442 | TOPICALLY-APPLIED PROBIOTIC TO TREAT DYSBIOSIS IN THE SKIN MICROBIOME OF PETS AND OTHER ANIMALS | May 2021 | November 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17224009 | USE OF CHROMIUM HISTIDINATE FOR TREATMENT OF CARDIOMETABOLIC DISORDERS | April 2021 | November 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17222703 | BIODEGRADABLE DRUG DELIVERY COMPOSITION | April 2021 | September 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17190504 | FLAVONOIDS AND LINOLEIC ACID USES IN HYPERTENSION | March 2021 | October 2022 | Abandon | 20 | 4 | 1 | Yes | No |
| 17190329 | INHIBITION OF SPONTANEOUS METASTASIS VIA PROTEIN INHIBITORS OF CYSTEINE PROTEASES | March 2021 | September 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17186439 | SUBLINGUAL APOMORPHINE | February 2021 | December 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17167428 | METHOD OF TREATING A DISEASE USING A GLYCOLYTIC DEPENDENT COMPOUND | February 2021 | January 2024 | Allow | 35 | 3 | 0 | No | No |
| 17167703 | SAFENED HERBICIDAL COMPOSITIONS CONTAINING HALAUXIFEN AND METHODS OF USE THEREOF IN BRASSICA SPECIES | February 2021 | January 2025 | Abandon | 47 | 3 | 1 | No | No |
| 17156053 | PACKAGED MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED STABILITY | January 2021 | April 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17251440 | NOVEL KETOGENIC COMPOUNDS, COMPOSITIONS, METHODS AND USE THEREOF | December 2020 | January 2023 | Abandon | 26 | 2 | 1 | No | No |
| 17113908 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF EYELID SWELLING | December 2020 | October 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17112742 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | December 2020 | September 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16949756 | Aluminum-Free Antiperspirant / Deodorant Compositions | November 2020 | July 2023 | Abandon | 32 | 3 | 1 | No | No |
| 17091489 | CELLULOSE NANOCRYSTAL-BASED EMULSIONS AND USES THEREOF | November 2020 | October 2024 | Abandon | 47 | 2 | 1 | Yes | No |
| 17086502 | GLASS STRUCTURE AND METHOD FOR PRODUCING THE SAME | November 2020 | August 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17073326 | SURFACES COMPRISING ATTACHED QUORUM SENSING MODULATORS | October 2020 | April 2025 | Abandon | 54 | 3 | 1 | No | No |
| 17046538 | USE OF A NEW COMPOSITION FOR PREVENTING OR SLOWING THE APPEARANCE OF SIGNS OF INFLAMMATION | October 2020 | May 2025 | Allow | 55 | 2 | 1 | No | No |
| 17030519 | SYNTHETIC PLATELETS | September 2020 | August 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17016528 | METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING | September 2020 | July 2024 | Allow | 46 | 6 | 1 | No | Yes |
| 16979487 | Method of Treating Ciliated Tissue Using CSA Micelles | September 2020 | April 2024 | Allow | 43 | 4 | 1 | No | No |
| 17002266 | METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING | August 2020 | August 2024 | Abandon | 48 | 3 | 1 | No | No |
| 16997983 | METHODS FOR SEQUESTERING CARBON OF ORGANIC MATERIALS | August 2020 | January 2022 | Abandon | 17 | 2 | 1 | No | No |
| 16995362 | Compositions, Methods and/or Devices for Prevention and/or Treatment of Dry Eye Disorders | August 2020 | October 2024 | Abandon | 50 | 5 | 1 | Yes | No |
| 16969292 | Pharmaceutical Composition of Brigatinib | August 2020 | August 2023 | Abandon | 36 | 1 | 1 | No | No |
| 16989295 | COMBINATION FORMULATION CONTAINING SUSTAINED RELEASE METFORMIN AND IMMEDIATE RELEASE HMG-COA REDUCTASE INHIBITOR | August 2020 | March 2023 | Abandon | 31 | 0 | 1 | No | No |
| 16967533 | GAMMA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | August 2020 | March 2025 | Allow | 55 | 2 | 1 | No | No |
| 16984645 | PACKAGED MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED STABILITY | August 2020 | April 2023 | Abandon | 32 | 5 | 1 | Yes | Yes |
| 16967265 | N-ACETYLCYSTEINE AND UREA-BASED FORMULATION FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | August 2020 | November 2024 | Abandon | 51 | 4 | 1 | No | No |
| 16945040 | AMINO ACID FORMULATIONS AND USES THEREOF | July 2020 | March 2025 | Abandon | 55 | 4 | 1 | Yes | Yes |
| 16966869 | ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOF | July 2020 | March 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16940787 | Formulations And Methods For Treating Photosynthetic Organisms And Enhancing Qualities And Quantities Of Yields With Glycan Composite Formulations | July 2020 | December 2023 | Allow | 41 | 2 | 0 | No | No |
| 16940784 | Formulations And Methods For Treating Photosynthetic Organisms And Enhancing Qualities And Quantities Of Yields With Glycan Composite Formulations | July 2020 | February 2025 | Allow | 55 | 7 | 0 | Yes | No |
| 16936678 | COMPOSITION OF PICKERING EMULSION COMPRISING LOW AMOUNT OF ALCOHOL | July 2020 | April 2025 | Abandon | 56 | 8 | 1 | Yes | No |
| 16935918 | SILICONE AND SILOXANE-BASED IMPREGNATED COATING AND POLYMERIC MATERIALS FOR CONDITIONING | July 2020 | November 2024 | Allow | 51 | 2 | 1 | No | Yes |
| 16963532 | A BASE AND PHARMACEUTICAL COMPOSITION CONTAINING IT | July 2020 | October 2024 | Allow | 51 | 3 | 1 | Yes | No |
| 16921965 | METHOD FOR ENCOURAGING BUDDING FROM GROWING POINT OF PLANT, FOR INHIBITING APICAL BUD GROWTH, AND FOR INCREASING NUMBER OF LATERAL SHOOTS, AND SUBSTANCES MADE BY AND USED IN THE METHOD | July 2020 | July 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16959357 | ORAL PHARMACEUTICAL FORMULATION COMPRISING CANNABINOIDS AND POLOXAMER | June 2020 | May 2024 | Abandon | 46 | 3 | 1 | No | No |
| 16958897 | EMULSIFIED COMPOSITION | June 2020 | December 2022 | Abandon | 30 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BROWE, DAVID.
With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BROWE, DAVID works in Art Unit 1617 and has examined 767 patent applications in our dataset. With an allowance rate of 22.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner BROWE, DAVID's allowance rate of 22.4% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BROWE, DAVID receive 3.12 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BROWE, DAVID is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +30.0% benefit to allowance rate for applications examined by BROWE, DAVID. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 5.6% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 17.4% of cases where such amendments are filed. This entry rate is in the 13% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 19.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 25% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 44.4% of appeals filed. This is in the 7% percentile among all examiners. Of these withdrawals, 25.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 60.2% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 57% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.